Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization

Modern Pathology

Volumn 20, Issue 11, 2007, Pages 1121-1127

  Popa, Ion ^a   Fradet, Yves ^b,c   Beaudry, Geneviève ^b   Hovington, Hélène ^b   Beaudry, Guillaume ^c   Têtu, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c DiagnoCure Inc   (Canada)

Author keywords

Chromogenic in situ hybridization; In situ hybridization; PCA3; Prostate carcinoma

Indexed keywords

CHROMOGENIC SUBSTRATE; FORMALDEHYDE; PARAFFIN; RADIOACTIVE MATERIAL; SULFUR 35; URIDINE TRIPHOSPHATE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; MARKER GENE; NUCLEOTIDE SEQUENCE; PCA3 GENE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; STAINING;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; AUTORADIOGRAPHY; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 35348955894     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800963     Document Type: Article

References (28)

1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-1427.
2. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003;97:3133-3275.
3. Terris MK. Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report. Urology 1999;54:486-489.
4. Naughton CK, Smith DS, Humphrey PA, et al. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998;52:808-813.
5. Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol 2005;12(Suppl 1): 44-48; discussion 99-100.
6. Verhaegh GW, van Bokhoven A, Smit F, et al. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000;275:37496-37503.
7. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979.
8. Schalken JA. Validation of molecular targets in prostate cancer. BJU Int 2005;96:23-29.
9. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34-43.
10. Gandini O, Santulli M, Cardillo MR, et al. Correspondence re: JB de Kok et al., DD3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-2698.
11. Cancer Res 2003; 63: 4747-4749.
12. Bussemakers MJ. Changes in gene expression and targets for therapy. Eur Urol 1999;35:408-412.
13. Schalken J. Molecular diagnostics and therapy of prostate cancer: new avenues. Eur Urol 1998;34 (Suppl 3):3-6.
14. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-2698.
15. Balcerczak E, Mirowski M, Sasor A, et al. Expression of p65, DD3 and c-erbB2 genes in prostate cancer. Neoplasma 2003;50:97-101.
16. Bialkowska-Hobrzanska H, Driman DK, Fletcher R, et al. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can J Urol 2006; 13:2967-2974.
17. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005;114:950-956.
18. Schmidt U, Fuessel S, Koch R, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006;66:1521-1534.
19. Thelen P, Burfeind P, Grzmil M, et al. cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and non-neoplastic prostate tissue separated by laser microdissections. Int J Oncol 2004;24:1085-1092.
20. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-3852.
21. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
22. Jung M, Xu C, Spethmann J, et al. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. Eur Urol 2004; 46: 271-272.
23. Marangoni K, Neves AF, Cardoso AM, et al. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev 2006;30:7-13.
24. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-315.
25. Tinzl M, Marberger M, Horvath S, et al. DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-186.
26. Hessels D, Klein Gunnewiek JM, van OI, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
27. Bostwick DG, Gould VE, Qian J, et al. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol 2006;19:630-633.
28. Groskopf J, Aubin SM, Deras IL, et al. Aptima PCA3 Molecular Urine Test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-1095.